2 news items
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VANI
26 Mar 24
filing a Complete Response to the current Clinical Hold on NPM-119 during the first half of 2024.
Vivani
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
VANI
28 Feb 24
) corrected to control (vehicle implant). Values are mean ± SE. (Photo: Business Wire)
"In response
- Prev
- 1
- Next